EGFR and metastatic colorectal cancer: Similarly, in 2006, Vectibix (panitumumab), the first fully human antibody generated from transgenic mice, was approved for the treatment of metastatic colorectal cancer by targeting the Epidermal Growth Factor Receptor (EGFR).